The published pregnenolone trials picked doses, 30 to 500 mg per day of an oral capsule, that fit the average adult enrolled in an adjunct-to-antipsychotic protocol or a 12-week bipolar-depression study. Those schedules were not calibrated to your baseline neurosteroid pool, your age (pregnenolone and DHEA decline measurably across the adult lifespan), your concurrent psychiatric regimen, whether you are using pregnenolone for cognition versus mood versus a cannabinoid-axis indication, or whether oral first-pass metabolism is the right route for what your prescriber is trying to achieve. The dietary supplement aisle is calibrated for even less than that, the doses available are whatever the brand decided to make.
That is the gap a compounding pharmacy fills on a patient-specific prescription. A clinician who knows the chart can write a strength outside the OTC increments (10 mg increments below the supplement floor for a careful titration, or trial-range doses with verified API potency for a clinical-research context), switch the dosage form to a sublingual troche when oral first-pass is the wrong fit, exclude an excipient the patient does not tolerate, or blend pregnenolone with related neurosteroid precursors when the protocol calls for it. Compounded preparations are not FDA-approved and the evidence base remains emerging, so the prescriber and pharmacist together carry the documentation that a specific patient's need is not met by the supplement market.
This is the older arrangement, a doctor who knows the patient, a pharmacist who prepares the medicine for that named person, a prescription that ties the two together. Modern 503A oversight, state licensure, named-on-label dispensing, and pharmacist review, keeps it honest.
In brief
Pregnenolone Explained
Pregnenolone is a steroid molecule the body makes from cholesterol. It sits at the top of the steroid family tree, your cells use it to build progesterone, DHEA, testosterone, estrogen, cortisol, and a group of brain-active steroids called neurosteroids. Because every other steroid hormone is downstream of pregnenolone, it is sometimes called the 'master steroid' or 'parent prohormone'.
Pregnenolone is sold over the counter in the United States as a dietary supplement under DSHEA. There is no FDA-approved prescription product. Researchers have studied oral pregnenolone, mostly at 30, 500 mg per day, as an add-on treatment in schizophrenia (cognitive and negative symptoms), as a stand-alone treatment for bipolar depression in a single trial, and in smaller imaging and biomarker studies in PTSD and traumatic brain injury 2316. Results are mixed and trials are generally small.
RonanRx compounds pregnenolone on a patient-specific prescription when the OTC supplement market does not meet a documented clinical need, for example a custom strength, verified API purity for a clinical research context, an alternative dosage form, or a preparation without a specific excipient 8. Compounded pregnenolone is not FDA-approved and is not a substitute for FDA-approved therapy for any condition 34.
At a glance
Quick Facts About Pregnenolone
Category
Endogenous neurosteroid; upstream precursor to all major steroid hormones
Common aliases
3β-hydroxy-5-pregnen-20-one; the 'master steroid' or 'parent prohormone' in lay literature
Biological role
Synthesized from cholesterol in mitochondria via CYP11A1; precursor to progesterone, allopregnanolone, DHEA, androgens, estrogens, and cortisol
Routes studied in humans
Oral capsule (clinical-trial standard at 30, 500 mg/day); sublingual tablet/troche used clinically though less directly studied
Evidence posture
Emerging. Multiple small randomized trials as adjunct in schizophrenia (cognitive and negative symptoms) with mixed signals; single RCT in bipolar depression; preclinical and small clinical work in PTSD, cannabis-related psychosis, and traumatic brain injury
FDA-approval status
Not FDA-approved for any indication. Marketed over the counter as a dietary supplement under DSHEA. No branded prescription product exists in the US.
Compounded under
503A, patient-specific prescription only
Compounded role
Pregnenolone exists as an OTC dietary supplement, so compounded preparations are appropriate when a documented patient need is not met by the supplement market, custom strengths, verified API purity and potency for a clinical context, exclusion of specific excipients, or alternative dosage forms such as sublingual troches.
Prescription review
Patient-Specific Prescription Only
Pregnenolone on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Pregnenolone?
Pregnenolone is a 21-carbon steroid with the systematic name 3β-hydroxy-5-pregnen-20-one 34. It is the immediate product of cholesterol side-chain cleavage catalyzed by CYP11A1 (also called P450scc) on the inner mitochondrial membrane, the rate-limiting and committed step of steroidogenesis. Once formed, pregnenolone exits the mitochondrion and is metabolized along multiple downstream pathways: to progesterone by 3β-hydroxysteroid dehydrogenase (and from progesterone onward to mineralocorticoids, glucocorticoids, and the neuroactive 5α-reduced steroid allopregnanolone); to 17α-hydroxypregnenolone and then DHEA by CYP17A1; and from DHEA onward to androgens and estrogens 8.
Pregnenolone is synthesized not only in the adrenal cortex and gonads but also locally in the brain by neurons and glia 34. Brain-synthesized steroids, including pregnenolone, pregnenolone sulfate, progesterone, allopregnanolone, and DHEA, are termed neurosteroids. They act through both classical nuclear receptors (after downstream conversion) and rapid, non-genomic modulation of ligand-gated ion channels, principally the GABA-A and NMDA receptors 3230.
Pregnenolone has been available pharmaceutically and as a dietary supplement since the 1940s. In the United States it is currently sold over the counter under DSHEA, typically as oral capsules at 10, 100 mg. There is no FDA-approved prescription pregnenolone product. Compounded oral capsules and sublingual troches are dispensed under 503A on patient-specific prescriptions where the OTC supplement market does not meet a documented clinical need 34.
How it works
How Pregnenolone Works
Class
Steroid precursor
First studied
1940s
Common forms
Oral capsule
Compounding category
503A, patient-specific prescription
Pregnenolone has two mechanistically distinct roles that the literature does not always cleanly separate. First, it is the upstream precursor to most physiologically important steroid hormones, so administered pregnenolone can in principle raise downstream steroid pools, progesterone, allopregnanolone, DHEA, and the steroids further downstream 8. Second, pregnenolone and its sulfate metabolite have direct neuromodulatory activity at GABA-A and NMDA receptors, independent of conversion 32.
Allopregnanolone, a downstream metabolite of pregnenolone via progesterone and 5α-dihydroprogesterone, is one of the most potent endogenous positive allosteric modulators of GABA-A receptors known 30. Sripada and colleagues demonstrated in healthy adults that a 400 mg oral dose of pregnenolone meaningfully elevates serum allopregnanolone and shifts activation of cortical and subcortical emotion-regulation circuits, providing direct evidence that oral pregnenolone reaches the CNS and engages the downstream neurosteroid pathway in humans 1819.
Pregnenolone sulfate is a different molecule pharmacologically. It is a negative allosteric modulator of GABA-A receptors and a positive modulator of NMDA receptors, and it has been studied preclinically for cognition-enhancing effects 14. The relative contributions of unconjugated pregnenolone, pregnenolone sulfate, allopregnanolone, and other downstream steroids to any clinical effect of administered pregnenolone are not fully resolved and likely differ by indication.
Research history
Pregnenolone Research History
Pregnenolone was isolated and named in the 1930s during the early steroid-biochemistry era. Through the 1940s and 1950s, pregnenolone was investigated clinically in arthritis and as a general fatigue or 'tonic' remedy, with mixed and largely uncontrolled results; this body of work fell out of mainstream pharmacology when more specific steroid therapies (cortisone, estrogens, testosterone esters) became available 8. The molecule remained available pharmaceutically and, after DSHEA passed in 1994, as a dietary supplement.
Modern interest in pregnenolone as a clinical agent dates to the neurosteroid era opened by Baulieu and colleagues in the 1980s, who demonstrated that the brain synthesizes pregnenolone and its sulfate ester locally 8. Pharmacological characterization of pregnenolone sulfate as a positive modulator of NMDA receptors and a negative modulator of GABA-A receptors, and of allopregnanolone (a downstream metabolite) as a potent positive modulator of GABA-A receptors, was completed across the 1990s and 2000s 32.
George and colleagues in 1994 reported altered CSF pregnenolone, progesterone, and DBI in affective disorders 17. Marx and colleagues at Duke and the Mid-Atlantic MIRECC published a key 2006 paper demonstrating altered neuroactive steroid levels in schizophrenia and bipolar disorder, providing the rationale for the subsequent randomized trials 11. Ritsner and colleagues characterized blood pregnenolone and DHEA differences between schizophrenia patients and healthy controls in 2007 98.
The clinical-trial era for pregnenolone in schizophrenia opened with Marx and colleagues' 2009 proof-of-concept randomized placebo-controlled trial of adjunctive pregnenolone (up to 500 mg/day) in 18 adults with schizophrenia or schizoaffective disorder, which reported improvement in negative symptoms and selected cognitive domains 1. Ritsner's 2010 8-week randomized trial of pregnenolone, DHEA, pregnenolone + DHEA, and placebo as augmentation in schizophrenia and schizoaffective disorder followed 5. Marx and colleagues' 2014 follow-on multi-site proof-of-concept RCT in Singapore 2, and Ritsner and Kreinin's 8-week recent-onset schizophrenia trials of pregnenolone for negative symptoms 3 and cognitive deficits 4, extended the evidence base 8. Kashani 2017 reported a risperidone-adjunct trial in women 6 and Kardashev 2018 a pregnenolone + L-theanine combination trial 7. Heringa 2015 published a quantitative review of sex-hormone augmentation strategies in schizophrenia 12; Ritsner 2010 had earlier reviewed the broader pregnenolone/DHEA schizophrenia literature 10.
Brown and colleagues at UT Southwestern published the only randomized placebo-controlled trial of pregnenolone in bipolar depression in 2014 16. fMRI work from Sripada and the Liberzon group at Michigan demonstrated in 2013 and 2014 that oral pregnenolone administration in healthy adults elevates allopregnanolone and modulates emotion-regulation neurocircuitry and resting-state amygdala connectivity 1819, providing mechanistic human imaging evidence 8.
The cannabinoid-axis work is more recent. Vallée and colleagues at INSERM demonstrated that pregnenolone is an endogenous CB1 negative allosteric modulator and that pregnenolone administration blocked cannabinoid-induced acute psychotic-like states in mice 2315. Frau and colleagues in 2019 showed that pregnenolone reverses the hyperdopaminergic phenotype of prenatal-THC-exposed offspring 24, with sex-specific extension in 2023 25. Mason and colleagues' 2017 study of neurosteroid levels in bipolar disorder with cannabis use disorder highlighted the same axis clinically 27; Raux and Vallée reviewed the neurosteroid-endocannabinoid cross-talk in 2023 26. Tomaselli and Vallée's 2019 review consolidated the pregnenolone-progesterone-allopregnanolone pathway in stress and addiction 29.
PTSD and TBI neurosteroid research has remained largely observational. Marx and colleagues at the Mid-Atlantic MIRECC have published a series of post-mortem and CSF studies, neurosteroid levels in PTSD orbital frontal cortex 20, cortical thickness associations 22, and TBI rodent neurosteroid changes 21. Peltier and colleagues' 2024 review consolidated the decade of clinical neurosteroid data in PTSD and alcohol use disorder 28. There is no completed adequately powered RCT of pregnenolone for PTSD, TBI, or cannabis use disorder. The FDA approvals of brexanolone (2019) and zuranolone (2023) for postpartum depression, both downstream allopregnanolone-pathway therapeutics, have intensified interest in the broader neurosteroid program but do not extend to pregnenolone itself 338.
Timeline
Pregnenolone Timeline
1930sPregnenolone first isolated and characterized during the early steroid-biochemistry era; named for its progesterone relationship
1940s, 1950sPregnenolone investigated clinically in arthritis and as a general 'tonic' agent; results largely uncontrolled and the molecule falls out of mainstream pharmacology when more specific steroid therapies become available
1980sBaulieu and colleagues establish that the brain synthesizes pregnenolone and pregnenolone sulfate de novo, opening the modern neurosteroid era
1994DSHEA passes; pregnenolone becomes a dietary supplement in the US 3217. Holsboer and colleagues publish steroid effects on central neurons; George and colleagues report altered CSF pregnenolone/progesterone/DBI in affective disorders
2006Marx et al publish 'Neuroactive steroids are altered in schizophrenia and bipolar disorder' (Neuropsychopharmacology), anchors the rationale for the subsequent schizophrenia adjunct trials 11
2007Ritsner et al characterize differences in blood pregnenolone and DHEA between schizophrenia patients and healthy controls 9
2009Marx et al publish the first proof-of-concept RCT of adjunctive pregnenolone in schizophrenia (Neuropsychopharmacology), reporting improvement in negative symptoms and selected cognitive domains 1
2010Ritsner et al publish 8-week randomized trial of pregnenolone, DHEA, and pregnenolone + DHEA as augmentation in schizophrenia and schizoaffective disorder 5
2011Marx et al publish 'Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence' (Neuroscience), comprehensive mechanism + clinical synthesis 8
2012Wong et al show pregnenolone rescues schizophrenia-like behavior in dopamine-transporter knockout mice (PLoS One) 15
2013Sripada et al publish fMRI study showing oral pregnenolone elevates allopregnanolone and enhances emotion-regulation neurocircuit activation in healthy adults (Biol Psychiatry) 18
2014Marx et al publish multi-site RCT of pregnenolone in schizophrenia (Psychopharmacology); Ritsner-Kreinin 8-week recent-onset schizophrenia negative-symptom trial; Brown et al publish the only RCT of pregnenolone in bipolar depression (Neuropsychopharmacology); Sripada et al publish allopregnanolone/DHEA amygdala connectivity fMRI work 231619
2015Heringa et al publish quantitative review of sex-hormone augmentation strategies in schizophrenia; Frau et al show that targeting neurosteroid synthesis ameliorates schizophrenia-related alterations from early psychosocial stress 1213
2017Kreinin/Ritsner publish 8-week recent-onset schizophrenia cognition trial (positive cognitive signal); Kashani et al publish risperidone-adjunct trial in women with schizophrenia; Mason et al examine neurosteroid levels in bipolar disorder with cannabis use disorders; Busquets-Garcia/Vallée show pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice (Mol Psychiatry); Locci and Pinna characterize stress-induced neurosteroid down-regulation and GABA-A subunit changes 46272331
2018Kardashev et al publish pregnenolone + L-theanine adjunct trial in schizophrenia; Rajagopal et al show pregnenolone sulfate augmentation reverses PCP-induced cognitive and social deficits preclinically 714
2019Frau et al show prenatal THC produces a hyperdopaminergic phenotype rescued by pregnenolone (Nat Neurosci); Cruz et al examine neurosteroid levels in the orbital frontal cortex of subjects with PTSD; Morey et al associate cortical thickness with neuroactive steroid levels; Tomaselli and Vallée publish a comprehensive pregnenolone-progesterone-allopregnanolone pathway review 24202229
2020Boero et al publish 'Pleiotropic actions of allopregnanolone underlie therapeutic benefits in stress-related disease' (Neurobiol Stress), consolidates downstream neurosteroid pharmacology 30
2023Frau and Melis publish sex-specific susceptibility to prenatal THC and reversal by pregnenolone; Raux and Vallée review cross-talk between neurosteroid and endocannabinoid systems in cannabis addiction; Marecki et al publish a narrative review on zuranolone, synthetic neurosteroid context for the broader pathway 252633
2024Peltier et al publish 10-year clinical review of neurosteroids in PTSD and alcohol use disorder 28
Natural role
Biological Role of Pregnenolone
Endogenous pregnenolone is synthesized continuously from cholesterol in the adrenal cortex, gonads, placenta during pregnancy, and locally within the central nervous system by neurons and glia. The brain-synthesized pool, together with downstream conversion products allopregnanolone, pregnenolone sulfate, DHEA, and DHEA-sulfate, comprises the principal endogenous neurosteroid pool 830.
Serum and CSF pregnenolone fluctuate with normal hormonal physiology and decline with age, paralleling the well-described age-related decline in DHEA and DHEA-sulfate. Altered neurosteroid levels have been documented in major psychiatric and neurological disorders including schizophrenia, bipolar disorder, major depression, PTSD, and traumatic brain injury 1120. Whether these alterations are causal, compensatory, or epiphenomenal is not resolved.
Because pregnenolone sits at the top of the steroidogenic cascade, exogenous administration in principle expands all downstream steroid pools, including progesterone, allopregnanolone, DHEA, and the sex steroids and glucocorticoids downstream of those 17. The clinical consequence in humans of supplementation is incompletely characterized: the directly demonstrated effect in healthy adults is elevation of allopregnanolone with corresponding fMRI changes in emotion-regulation circuits 18, but broader endocrine effects of sustained pregnenolone supplementation across the population have not been systematically mapped 9.
Off-label use
Off-Label Uses of Pregnenolone
Adjunct in schizophrenia (negative symptoms and cognition) emerging
Studied as an add-on to antipsychotic therapy in several small randomized placebo-controlled trials; signals are mixed and effect sizes vary by trial. Evidence remains preliminary.
Marx 2009 (n=18) reported improvement in negative symptoms and selected cognitive domains on adjunctive pregnenolone up to 500 mg/day 12. Ritsner 2010 (n=58) compared pregnenolone, DHEA, the combination, and placebo over 8 weeks 5. Marx 2014 (n=120) was a multi-site RCT with a more modest signal. Ritsner-Kreinin 2014 and Kreinin 2017 reported negative-symptom and cognitive improvements in recent-onset schizophrenia 34. Kashani 2017 added pregnenolone to risperidone in women 6. Kardashev 2018 combined pregnenolone with L-theanine 7. Heringa 2015's quantitative review of sex-hormone augmentation in schizophrenia integrated the data and concluded the evidence remains preliminary 12.
Single 12-week RCT supports an exploratory signal; no replication.
Brown et al (2014) randomized 80 adults with bipolar depression to pregnenolone 500 mg/day or placebo over 12 weeks 16. Pregnenolone produced a greater reduction in depressive symptoms than placebo. No replication trial has been published; the signal sits in the same exploratory tier as the schizophrenia adjunct literature.
Mechanistic and biomarker work supports an association between altered neurosteroid biology and PTSD; no adequately powered RCT of pregnenolone is completed.
Cruz 2019 documented altered neurosteroid levels in PTSD orbital frontal cortex 20. Morey 2019 associated serum neuroactive steroids, including pregnenolone, with cortical-thickness MRI markers in stress-exposed populations 22. Sripada 2013/2014 demonstrated that exogenous pregnenolone elevates allopregnanolone and modulates emotion-regulation and amygdala-connectivity fMRI signatures in healthy adults 1819. Peltier 2024 consolidated 10 years of clinical neurosteroid data in PTSD and AUD 28. The PTSD literature remains primarily biomarker- and imaging-driven; clinical efficacy of pregnenolone in PTSD is not established.
Strong preclinical mechanistic basis via CB1 allosteric modulation; clinical evidence in humans remains preliminary.
Pregnenolone is an endogenous negative allosteric modulator at CB1. Busquets-Garcia/Vallée 2017 reported that pregnenolone administration blocked cannabinoid-induced acute psychotic-like states in mice 2325. Frau 2019 and Frau-Melis 2023 demonstrated rescue of prenatal-THC-induced hyperdopaminergic phenotypes 24. Mason 2017 documented altered neurosteroid levels in bipolar disorder with co-occurring cannabis use disorders 2729. Raux and Vallée 2023 and Tomaselli-Vallée 2019 reviewed the cross-talk 26. Adequately powered human RCTs in cannabis use disorder or cannabis-related psychosis are not yet completed.
Rodent stress + mTBI models show neurosteroid changes; clinical translation is preliminary.
Servatius 2016 documented elevation of brain and serum androsterone in response to stress in rats with mild TBI 21. Marx and colleagues have published a series of post-mortem and biomarker studies on neurosteroid changes after brain injury. There is no published completed randomized trial of pregnenolone for traumatic brain injury in humans.
Compounded use
Compounded Pregnenolone (503A)
Pregnenolone is sold over the counter in the United States as a dietary supplement under DSHEA, typically as oral capsules at 10, 100 mg. There is no FDA-approved prescription pregnenolone product. The 'essentially-a-copy' framing that governs much of 503A compounding does not apply here in the usual way, there is no FDA-approved branded product to copy 34.
Compounded pregnenolone has a legitimate 503A role when a documented patient-specific clinical need cannot be met by the OTC supplement market 28. Common reasons include: a custom strength outside available supplement increments; verified API purity, potency, and identity for a clinical-care context where supplement-grade verification is insufficient; exclusion of specific excipients (fillers, dyes, or allergens present in the patient's available supplement options); or an alternative dosage form, such as a sublingual troche, that the supplement market does not offer. RonanRx does not compound pregnenolone as a routine substitute for a commercially available OTC supplement absent such documented patient-specific need.
Patients and prescribers should also recognize that any decision to administer pregnenolone, compounded or supplement, sits on an emerging evidence base. The principal psychiatric trials are small, often single-site, and concentrated in the schizophrenia adjunct space with one bipolar depression trial; cognitive-aging, PTSD, TBI, and cannabis-related indications have either no completed RCT or only exploratory biomarker work 16. Pregnenolone is not a substitute for any FDA-approved therapy for any psychiatric, neurological, or endocrine condition 2.
Formulations and routes
Pregnenolone Formulations and Routes
Form
Concentration
Description
Oral capsule
Custom; published trial strengths span 30, 500 mg/day
Custom-strength oral capsules, the dose form used in essentially all published randomized clinical trials of pregnenolone, including the Marx and Ritsner schizophrenia program and Brown's bipolar depression RCT125316
Sublingual troche or tablet
Custom
Alternative dosage form prepared on patient-specific prescription when oral capsule administration is not appropriate; less directly studied in randomized trials but used clinically
Routes used in published literature: oral, sublingual, troche.
Dosing
Pregnenolone Dosing
Route
Population
Range
Duration
Study type
oral capsule
adults with schizophrenia (adjunct)
30, 500 mg/day, titrated; Marx 2009 used 500 mg/day, Marx 2014 used 500 mg/day, Ritsner studies used 50, 150 mg/day
Doses listed reflect published clinical-trial protocols, not RonanRx prescribing recommendations. The prescribing doctor selects route, dose, frequency, and duration based on the patient's clinical context, indication, and goals.
Pregnenolone trial-dose ranges are wide (30, 500 mg/day) and indication-dependent. The schizophrenia adjunct trials clustered at 50, 500 mg/day; the only bipolar depression RCT used 500 mg/day; the human fMRI mechanistic work used 400 mg single doses. Optimal dose for any other indication is not established by published clinical data. Doses listed should not be presented to patients as instructions, patient instructions originate from the prescribing physician's prescription.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Pregnenolone Safety
Safety overview
Across the randomized clinical trials of oral pregnenolone in schizophrenia and bipolar depression, pregnenolone has been generally well-tolerated at trial doses (up to 500 mg/day for 8, 12 weeks) with adverse-event rates comparable to placebo in most studies 512. Reported adverse effects are typically mild, drowsiness, headache, occasional gastrointestinal upset, and have not differentiated pregnenolone from placebo in a clinically meaningful way in the published trials 16.
The principal theoretical safety consideration is that pregnenolone is upstream of every steroid hormone class. Sustained supraphysiologic dosing could in principle elevate progesterone, allopregnanolone, DHEA, androgens, estrogens, and glucocorticoids, with associated downstream endocrine effects. The clinical trials reviewed have been too short and too small to characterize chronic endocrine effects of sustained pregnenolone supplementation, and routine monitoring practice for chronic exogenous pregnenolone has not been standardized 534. Patients with hormone-sensitive conditions (history of breast, prostate, or other steroid-responsive cancers; estrogen-dependent disorders; androgen-related dermatologic conditions) require particular clinical caution and prescriber-directed monitoring.
Contraindications
Honest gap. No FDA-approved prescription pregnenolone product exists, so no FDA-defined contraindications. Documented hypersensitivity to any component of a particular preparation is a relative contraindication for that preparation. Theoretical contraindications, derived from pregnenolone's upstream position in the steroid cascade, include pregnancy and lactation (unknown effects on fetal/neonatal steroid biology), hormone-sensitive cancers, and other steroid-responsive disorders pending prescriber-directed risk assessment.
Honest gap. No specific drug-drug interactions are formally established for pregnenolone. Theoretical interactions, derived from pregnenolone's metabolism through CYP and 3β-/17β-HSD enzymes, include other steroid hormone therapies (testosterone, estradiol, progesterone, DHEA, glucocorticoids) where supplementation may shift the balance between the administered hormone and the endogenous steroid pool. Patients taking antipsychotics, antidepressants, mood stabilizers, or other CNS-active medications should have any pregnenolone use coordinated with the prescribing psychiatrist or neurologist; the published adjunct trials specifically combined pregnenolone with antipsychotic or antidepressant base therapy under protocol supervision.
Searched: PubMed, DailyMed on 2026-05-11 · terms pregnenolone drug interactions; pregnenolone CYP; pregnenolone hormonal therapy.
Adverse events
In the published randomized trials of oral pregnenolone at trial doses (30, 500 mg/day for 8, 12 weeks), adverse-event rates did not differ clinically meaningfully from placebo 5316. Most-commonly reported mild adverse events across studies include drowsiness, headache, transient gastrointestinal upset, and dizziness; serious adverse events have been rare and not consistently attributable to pregnenolone.
Longer-term adverse-event characterization is limited. Theoretical endocrine consequences of sustained supplementation, through expansion of downstream steroid pools, have not been systematically mapped in the trial literature. Reports of mood disturbance, headache, irritability, or breast or skin changes attributed to pregnenolone supplements appear in the broader OTC literature but are not consistently reproduced in controlled trials 512.
Monitoring
Monitoring Pregnenolone Therapy
Routine laboratory monitoring is not standardized for pregnenolone supplementation or compounded use. The prescribing clinician may monitor disease-specific outcomes (psychiatric symptom scales, PTSD or depression rating instruments, cognitive testing) at clinically appropriate intervals consistent with the prescribed indication.
Where there is concern about downstream endocrine effects, particularly with sustained higher-dose use or in patients with hormone-sensitive conditions, the prescribing clinician may consider baseline and on-therapy steroid panels (pregnenolone, DHEA-sulfate, progesterone, testosterone, estradiol, cortisol) at intervals consistent with the patient's clinical context. Standardized monitoring intervals are not established in the published trial literature.
Evidence quality
Pregnenolone Evidence Quality
Evidence for pregnenolone as a therapeutic agent is emerging across all indications. The strongest signal, adjunct use in schizophrenia for negative symptoms and selected cognitive domains, rests on four small randomized placebo-controlled trials 1, one combination-augmentation trial (Ritsner 2010 pregnenolone + DHEA), one risperidone-adjunct trial 6, and one combination trial 7. Heringa's 2015 quantitative review of sex-hormone augmentation strategies integrated these data and concluded the evidence remained preliminary 12. Effect sizes vary by trial; pivotal multi-site trials of pregnenolone alone in schizophrenia have not been completed 245.
Bipolar depression rests on a single 12-week RCT 16 with a positive signal that has not been independently replicated 3. PTSD evidence is observational, imaging-based, and biomarker-focused 20. Cannabis-axis evidence is preclinical and mechanistic (Busquets-Garcia/Vallée 2017, Frau 2019, Frau-Melis 2023, Raux-Vallée 2023). Traumatic brain injury is rodent-stage. Cognitive aging and broader mood indications are anecdotal and supplement-market-driven rather than trial-supported.
Mechanism is reasonably well established at the biochemical level, CYP11A1-mediated synthesis, downstream conversion to allopregnanolone and other neurosteroids, GABA-A and NMDA receptor modulation by pregnenolone sulfate, CB1 allosteric modulation 19. Human imaging work 18 confirms that orally administered pregnenolone reaches the CNS and engages the downstream neurosteroid pathway 2324. The gap between mechanism and confirmed clinical benefit is real and should be communicated clearly to patients considering use 2228.
Adjunctive pregnenolone (up to 500 mg/day) produced improvement in negative symptoms and selected cognitive domains in adults with schizophrenia or schizoaffective disorder on stable antipsychotic therapy 1.
Compared pregnenolone, DHEA, pregnenolone + DHEA, and placebo as augmentation in schizophrenia and schizoaffective disorder; pregnenolone-containing arms produced measurable changes in selected outcomes vs placebo, with overall effect size modest 5.
Adjunctive pregnenolone in adults with chronic schizophrenia on antipsychotic therapy; modest signals on selected cognitive and symptom outcomes; effect size smaller than the 2009 proof-of-concept trial 2.
Pregnenolone 500 mg/day produced greater reduction in depressive symptoms than placebo in adults with bipolar depression. Only RCT of pregnenolone in bipolar depression to date 16.
Randomized double-blind placebo-controlled crossover fMRI study
—
Single dose
Single 400 mg oral dose of pregnenolone elevated serum allopregnanolone and enhanced activation of emotion-regulation neurocircuits (medial prefrontal cortex and amygdala) in healthy adults 18.
Documented altered pregnenolone, allopregnanolone, and DHEA levels in postmortem brain tissue and serum from individuals with schizophrenia and bipolar disorder vs controls, anchors the rationale for the subsequent adjunct trials 11.
Pregnenolone administration prevented cannabinoid-induced acute psychotic-like states in mice, via CB1 allosteric negative modulation 23. Defines the cannabinoid-axis mechanism for pregnenolone.
Prenatal THC exposure produced a hyperdopaminergic phenotype in offspring that was rescued by pregnenolone administration, supporting a clinical rationale in cannabis-related psychiatric outcomes 24.
Integrated published trials of sex-hormone and neurosteroid augmentation strategies in schizophrenia (including pregnenolone, DHEA, estrogen, raloxifene, oxytocin); concluded the evidence remained preliminary and called for adequately powered trials 12.
Consolidated 10 years of clinical neurosteroid data in PTSD and alcohol use disorder; framed pregnenolone and allopregnanolone as candidate biomarkers and modulators but did not identify any completed adequately powered RCT of pregnenolone for PTSD or AUD 28.
Consolidated allopregnanolone pharmacology and therapeutic relevance across stress-related disease, frames the downstream pathway that pregnenolone supplementation engages 30.
Mechanism detail
Detailed Mechanism of Pregnenolone
Steroidogenesis and the position of pregnenolone. CYP11A1, expressed on the inner mitochondrial membrane of steroidogenic cells in the adrenal cortex, gonads, placenta, and central nervous system, cleaves the side chain of cholesterol to yield pregnenolone, isocaproaldehyde, and water. This is the rate-limiting and committed step of de novo steroidogenesis: every other steroid hormone class, progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens, is synthesized from pregnenolone by tissue-specific complements of downstream enzymes. The traditional 'master steroid' framing reflects this anatomical position in the pathway 8.
Downstream neurosteroid pathway. Pregnenolone is converted to progesterone by 3β-hydroxysteroid dehydrogenase, progesterone to 5α-dihydroprogesterone by 5α-reductase, and 5α-dihydroprogesterone to allopregnanolone (3α,5α-tetrahydroprogesterone) by 3α-hydroxysteroid oxidoreductase. Allopregnanolone binds at a steroid-recognition site distinct from the benzodiazepine and barbiturate sites on the GABA-A receptor and enhances both phasic and tonic GABAergic inhibition. Allopregnanolone-mediated GABAergic tone is the proximate mechanism shared by zuranolone and brexanolone, the two FDA-approved neurosteroid therapeutics for postpartum depression, and is the rationale for testing pregnenolone, as a precursor, in stress-related, mood, and cognitive indications 3033.
Direct receptor pharmacology. Beyond serving as a precursor, pregnenolone and pregnenolone sulfate have direct effects on ligand-gated channels. Pregnenolone sulfate is a negative allosteric modulator of GABA-A receptors (opposite in sign to allopregnanolone) and a positive modulator of NMDA receptors; it has been associated with enhanced long-term potentiation in hippocampus and pro-cognitive effects in animal models 3214. Pregnenolone itself signals through the microtubule-associated protein MAP2 and modulates microtubule dynamics, a non-receptor pathway implicated in neurite outgrowth and possibly in some of pregnenolone's cognitive effects in preclinical models 8.
Cannabinoid axis. Pregnenolone is also an endogenous, allosteric negative feedback signal at the CB1 cannabinoid receptor. Vallée and colleagues demonstrated that THC raises brain pregnenolone, which then binds an allosteric site on CB1 and dampens THC's downstream signaling, a feedback loop that pregnenolone administration can amplify 23. Subsequent preclinical work reported that pregnenolone administration blocked and reversed cannabinoid-induced psychotic-like states in mice, attenuated the hyperdopaminergic phenotype of prenatal-THC-exposed offspring, and modulated the neurosteroid-endocannabinoid cross-talk implicated in cannabis use disorder 242526. This mechanism positions pregnenolone as a candidate adjunct in cannabis-related psychiatric phenotypes, though human trial evidence remains limited.
Stress and PTSD biology. Stress-related disorders are associated with altered neurosteroid biology. Locci and Pinna characterized a stress-induced down-regulation of neurosteroid biosynthesis paired with changes in GABA-A receptor subunit composition, a biomarker axis relevant to cognitive and emotional impairment 31. PTSD cohorts show altered CSF and post-mortem neurosteroid levels 20, serum pregnenolone, allopregnanolone, and DHEA track with cortical-thickness and white-matter MRI markers in stress-exposed populations 22, and traumatic-brain-injury rodent models show acute and chronic neurosteroid changes 21. Peltier and colleagues' 2024 review consolidated a decade of clinical neurosteroid data in PTSD and alcohol use disorder, framing pregnenolone and allopregnanolone as candidate biomarkers and modulators 28.
Schizophrenia rationale. Pregnenolone, DHEA, allopregnanolone, and related steroids are altered in postmortem and serum samples from individuals with schizophrenia and bipolar disorder 11927. Marx and colleagues' clinical program in schizophrenia rests on three convergent rationales: replacement of altered endogenous neurosteroid tone, GABA-A enhancement via allopregnanolone, and NMDA-receptor modulation via pregnenolone sulfate (relevant to the NMDA-hypofunction model of schizophrenia) 8. Preclinical work supports the rationale: pregnenolone rescues schizophrenia-like behavior in dopamine-transporter-knockout mice 15 and pregnenolone sulfate reverses phencyclidine-induced cognitive and social deficits 14; an early-life psychosocial-stress model showed that targeting neurosteroid synthesis ameliorated schizophrenia-related alterations 13.
Pharmacology
Pregnenolone Pharmacokinetics & Pharmacodynamics
Pharmacokinetics
Oral pregnenolone is absorbed but undergoes extensive first-pass metabolism through downstream steroidogenic pathways, so the principal pharmacologic exposure in humans is to a mixture of pregnenolone plus its metabolites, pregnenolone sulfate, progesterone, allopregnanolone, DHEA, DHEA-sulfate, and further downstream products. Direct measurement of the human PK of an oral pregnenolone dose to all clinically relevant downstream pools is limited; the most quantitative human PK / PD work to date is Sripada and colleagues' 2013 demonstration that a single 400 mg oral dose meaningfully elevates serum allopregnanolone within hours and that the elevation correlates with measurable changes in emotion-regulation fMRI activation 1819.
Because every administered dose of pregnenolone enters the steroidogenic cascade, a 'selective' pregnenolone effect cannot be assumed from oral dosing. The clinical phenotype of supplementation reflects integrated effects across downstream pools, with relative contributions that depend on tissue-specific complements of conversion enzymes 8. Sublingual administration is hypothesized to attenuate first-pass conversion, but direct human PK comparisons of oral capsule vs sublingual administration in clinically relevant doses have not been published.
Pregnenolone and pregnenolone sulfate are excreted primarily through hepatic metabolism with biliary and urinary elimination of conjugated metabolites. Half-life of unconjugated pregnenolone in plasma is on the order of hours, but the indirect pharmacologic exposure via downstream steroid pools (progesterone, allopregnanolone, DHEA) is longer 8.
Pharmacodynamics
Pharmacodynamic effects reflect contributions from pregnenolone itself, pregnenolone sulfate, and downstream metabolites, most notably allopregnanolone at GABA-A receptors and pregnenolone sulfate at GABA-A (negative modulation) and NMDA (positive modulation) receptors 323014. Direct measurement of human CNS pharmacodynamic effects of oral pregnenolone is limited to the Sripada 2013/2014 fMRI program, which demonstrated allopregnanolone elevation and modulation of emotion-regulation and amygdala-connectivity signatures after acute dosing 1819.
Clinical pharmacodynamic endpoints studied in the randomized trials include psychiatric symptom rating scales (PANSS, MADRS, HAM-D), cognitive batteries (MATRICS, RBANS, selected MCCB domains), and global functioning measures 18. The magnitude of pharmacodynamic effect varies by trial and indication and has not been integrated into a population-PK/PD model.
Comparative formulations
Comparing Pregnenolone Formulations
The published clinical-trial literature is essentially limited to oral capsule administration. Marx and Ritsner's schizophrenia program, Brown's bipolar depression RCT, and the Sripada fMRI mechanistic work all used oral pregnenolone in micronized or USP-grade capsule form at 30, 500 mg/day 123. No randomized trial has directly compared oral capsule vs sublingual administration in a clinically relevant indication 16.
Sublingual troches and tablets are prepared on patient-specific prescriptions where the prescribing clinician judges the alternative delivery preferable, for example to attenuate first-pass conversion, to address swallowing difficulty, or to permit titration finer than oral capsule increments allow. The hypothesized PK rationale is plausible but not directly validated in human clinical studies. Patients and prescribers should not assume bioequivalence between oral capsule and sublingual administration 18.
Storage
Pregnenolone Storage and Handling
Compounded oral capsules and sublingual preparations of pregnenolone are stored at controlled room temperature (USP 20, 25 °C) in tight, light-resistant containers per dispensing pharmacy labeling. Beyond-use dates are assigned per USP General Chapter <795> for nonsterile compounded preparations and the specific stability data for each formulation 35. Pregnenolone is a stable steroid at room temperature in dry conditions; refrigeration is not required for typical solid dosage forms.
RonanRx operations
Pregnenolone Compounding & Operations
503A compounding
RonanRx prepares pregnenolone under 503A on patient-specific prescriptions written by a licensed prescribing physician for an identified patient, consistent with section 503A of the Federal Food, Drug, and Cosmetic Act 34. Because pregnenolone is sold OTC as a dietary supplement and no FDA-approved prescription product exists, the 'essentially-a-copy' framework of 503A does not apply in the usual way; the compounded role is defined by patient-specific need not met by the supplement market, custom strengths, verified API identity and potency, excipient exclusion, or alternative dosage forms.
Bulk drug substance is sourced from FDA-registered API suppliers, with documented certificates of analysis confirming identity, purity, and potency. Nonsterile compounded preparations (oral capsules, sublingual troches and tablets) follow USP General Chapter <795> standards for nonsterile pharmaceutical compounding 35. Finished product lot records are retained per state board of pharmacy retention requirements, with full traceability from API lot through dispensing.
Pharmacist review
Each prescription for compounded pregnenolone undergoes pharmacist review prior to dispensing. The review confirms a documented patient-specific clinical reason that the OTC supplement market does not meet the patient's need (custom strength, verified API purity for the clinical context, excipient exclusion, or alternative dosage form); absence of disqualifying clinical concerns documented in the prescription record (hormone-sensitive cancer history, pregnancy/lactation, etc., pending prescriber risk assessment); appropriate concomitant medication review; and a prescribed regimen consistent with published clinical-trial protocols or with a prescriber-documented patient-specific rationale.
RonanRx does not fill prescriptions that read as routine substitution of compounded pregnenolone for an OTC supplement absent documented patient-specific clinical rationale. Pregnenolone is dispensed by patient-specific prescription only; RonanRx is not a direct-to-consumer storefront 34.
Quality and traceability
Active pharmaceutical ingredient is sourced from FDA-registered facilities with documented certificates of analysis confirming identity, purity, and potency for each lot. Each compounded batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements with full traceability from API lot through dispensing.
Cold chain
Pregnenolone oral capsules and sublingual preparations are not cold-chain products. They ship at controlled room temperature in tight, light-resistant containers. Patients should store the preparation per pharmacy labeling at controlled room temperature and protect from excessive heat, humidity, and direct sunlight.
If pregnenolone is sold OTC, why would anyone get it compounded?
Most patients who take pregnenolone use the OTC supplement market. Compounded pregnenolone has a legitimate 503A role only when a documented patient-specific clinical need cannot be met by the supplement market, for example a custom strength outside available supplement increments, verified API purity and potency for a clinical-care context, exclusion of a specific excipient, or an alternative dosage form such as a sublingual troche. RonanRx does not compound pregnenolone as a routine substitute for a commercially available OTC supplement absent such documented need 34.
Why is pregnenolone sometimes called the 'master steroid'?
Because pregnenolone sits at the top of the steroid family tree. It is the immediate product of CYP11A1 cleavage of cholesterol in mitochondria, and every other steroid hormone class, progesterone and the neurosteroid allopregnanolone, DHEA, testosterone, estrogen, cortisol and the other glucocorticoids, aldosterone and the other mineralocorticoids, is built from pregnenolone by tissue-specific enzymes 8. The 'master steroid' label reflects this anatomical position in the cascade.
What conditions has pregnenolone been studied in?
Published randomized clinical trials of pregnenolone are concentrated in schizophrenia as an adjunct to antipsychotic therapy, for negative symptoms and selected cognitive domains 123. One 12-week RCT examined bipolar depression 16. Smaller imaging and biomarker studies have addressed PTSD, traumatic brain injury, and cannabis-related psychiatric phenotypes 20. Cognitive aging and general mood support are anecdotal and supplement-market-driven rather than trial-supported 4. Evidence quality is emerging across all of these indications; pivotal multi-site trials have not been completed 28.
Does pregnenolone work for memory or cognitive aging?
There is no completed adequately powered randomized trial of pregnenolone for healthy-adult cognitive aging or memory enhancement. The strongest cognitive signal in the human trial literature is the Kreinin 2017 trial in recent-onset schizophrenia, which reported improvement on selected cognitive domains in that specific clinical population 4. Preclinical work on pregnenolone sulfate suggests NMDA-modulated cognitive effects, but that does not translate directly to clinical benefit in healthy adults 14.
What about pregnenolone for PTSD or stress?
There is no completed adequately powered RCT of pregnenolone for PTSD. The clinical literature consists of biomarker and neuroimaging studies, neurosteroid levels in PTSD orbital frontal cortex, serum neuroactive-steroid associations with cortical-thickness MRI markers, and fMRI work showing that oral pregnenolone elevates allopregnanolone and modulates emotion-regulation neurocircuitry in healthy adults 202218. The mechanistic rationale is reasonable but clinical efficacy is not established 28.
How does pregnenolone interact with the cannabis system?
Pregnenolone is an endogenous negative allosteric modulator at the CB1 cannabinoid receptor. Vallée and colleagues showed that THC raises brain pregnenolone, which then dampens THC's downstream signaling. In preclinical work, pregnenolone administration blocked cannabinoid-induced acute psychotic-like states in mice and reversed the hyperdopaminergic phenotype of prenatal-THC-exposed offspring 232425. Human clinical trials in cannabis use disorder or cannabis-related psychosis have not been completed 26.
Is pregnenolone safe?
In published randomized trials at trial doses (30, 500 mg/day for 8, 12 weeks), oral pregnenolone has been generally well-tolerated with adverse-event rates comparable to placebo 2316. The theoretical safety concern is that pregnenolone is upstream of every steroid hormone class, so sustained supplementation can in principle elevate downstream steroid pools 1. Long-term endocrine effects are not well characterized in the trial literature, and patients with hormone-sensitive conditions require particular clinical caution. Pregnancy and lactation are theoretical contraindications pending prescriber risk assessment.
Does RonanRx sell pregnenolone directly to patients?
No. Compounded pregnenolone, where dispensed, requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical reason that the OTC supplement market does not meet the patient's need, plus pharmacist review before dispensing. RonanRx is not a direct-to-consumer storefront 34.
Clinician resource
Download the Pregnenolone Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[marx2014poc] Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, Chan E, Kilts JD, Buchanan RW, Wai EP, Verma S, Sim K, Hariram J, Jacob R, Keefe RS, Chong SA. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl). 2014. PMID 25030803. (accessed 2026-05-11)
[ritsner2014kreinin] Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and Clinical Neurosciences. 2014. PMID 24548129. (accessed 2026-05-11)
[kreinin2017cognition] Kreinin A, Bawakny N, Ritsner MS. Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Schizophrenia & Related Psychoses. 2017. PMID 24496044. (accessed 2026-05-11)
[ritsner2010preg_dhea] Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, Weizman A, Lerner V. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. Journal of Clinical Psychiatry. 2010. PMID 20584515. (accessed 2026-05-11)
[kashani2017risperidone] Kashani L, Shams N, Moazen-Zadeh E, Karkhaneh-Yousefi MA, Sadighi G, Khodaie-Ardakani MR, Rezaei F, Rahiminejad F, Akhondzadeh S. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. Journal of Psychiatric Research. 2017. PMID 28688338. (accessed 2026-05-11)
[kardashev2018ltheanine] Kardashev A, Ratner Y, Ritsner MS. Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Schizophrenia & Related Psychoses. 2018. PMID 26218236. (accessed 2026-05-11)
[marx2011candidate] Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience. 2011. PMID 21756978. (accessed 2026-05-11)
[ritsner2007blood_levels] Ritsner M, Maayan R, Gibel A, Weizman A. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. European Neuropsychopharmacology. 2007. PMID 17123790. (accessed 2026-05-11)
[ritsner2010review] Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neuroscience & Therapeutics. 2010. PMID 20070787. (accessed 2026-05-11)
[marx2006neurosteroids] Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006. PMID 16319920. (accessed 2026-05-11)
[heringa2015review] Heringa SM, Begemann MJ, Goverde AJ, Sommer IE. Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review. Schizophrenia Research. 2015. PMID 25914107. (accessed 2026-05-11)
[frau2015stress] Frau R, Abbiati F, Bini V, Casti A, Caruso D, Devoto P, Bortolato M. Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress. Schizophrenia Research. 2015. PMID 25999042. (accessed 2026-05-11)
[rajagopal2018ps_aug] Rajagopal L, Soni D, Meltzer HY. Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction. Behavioural Brain Research. 2018. PMID 29763637. (accessed 2026-05-11)
[brown2014bipolar] Brown ES, Park J, Marx CE, Hynan LS, Gardner C, Davila D, Nakamura A, Sunderajan P, Lo A, Holmes T. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology. 2014. PMID 24917198. (accessed 2026-05-11)
[george1994csf_affective] George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI. Biological Psychiatry. 1994. PMID 8043707. (accessed 2026-05-11)
[sripada2013allopreg] Sripada RK, Marx CE, King AP, Rampton JC, Ho SS, Liberzon I. Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biological Psychiatry. 2013. PMID 23348009. (accessed 2026-05-11)
[sripada2014amygdala] Sripada RK, Welsh RC, Marx CE, Liberzon I. The neurosteroids allopregnanolone and dehydroepiandrosterone modulate resting-state amygdala connectivity. Human Brain Mapping. 2014. PMID 24302681. (accessed 2026-05-11)
[cruz2019ptsd_ofc] Cruz DA, Glantz LA, McGaughey KD, Parke G, Shampine LJ, Kilts JD, Naylor JC, Marx CE, Williamson DE. Neurosteroid Levels in the Orbital Frontal Cortex of Subjects with PTSD and Controls: A Preliminary Report. Chronic Stress (Thousand Oaks). 2019. PMID 31276078. (accessed 2026-05-11)
[servatius2016tbi_androsterone] Servatius RJ, Marx CE, Sinha S, Avcu P, Kilts JD, Naylor JC, Pang KC. Brain and Serum Androsterone Is Elevated in Response to Stress in Rats with Mild Traumatic Brain Injury. Frontiers in Neuroscience. 2016. PMID 27616978. (accessed 2026-05-11)
[morey2019cortical_thickness] Morey RA, Davis SL, Haswell CC, Naylor JC, Kilts JD, Szabo ST, Shampine LJ, Parke GJ, Sun D, Swanson CA, Wagner HR, Mid-Atlantic MIRECC Workgroup, Marx CE. Widespread Cortical Thickness Is Associated With Neuroactive Steroid Levels. Frontiers in Neuroscience. 2019. PMID 31798395. (accessed 2026-05-11)
[busquets_garcia2017] Busquets-Garcia A, Soria-Gomez E, Redon B, Mackenbach Y, Vallee M, Chaouloff F, Varilh M, Ferreira G, Piazza PV, Marsicano G. Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Molecular Psychiatry. 2017. PMID 28220044. (accessed 2026-05-11)
[frau2019_thc] Frau R, Miczan V, Traccis F, Aroni S, Pongor CI, Saba P, Serra V, Sagheddu C, Fanni S, Congiu M, Devoto P, Cheer JF, Katona I, Melis M. Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. Nature Neuroscience. 2019. PMID 31611707. (accessed 2026-05-11)
[frau2023_thc] Frau R, Melis M. Sex-specific susceptibility to psychotic-like states provoked by prenatal THC exposure: Reversal by pregnenolone. Journal of Neuroendocrinology. 2023. PMID 36810840. (accessed 2026-05-11)
[raux2023_crosstalk] Raux PL, Vallee M. Cross-talk between neurosteroid and endocannabinoid systems in cannabis addiction. Journal of Neuroendocrinology. 2023. PMID 36043319. (accessed 2026-05-11)
[mason2017bipolar_cud] Mason BL, Van Enkevort E, Filbey F, Marx CE, Park J, Nakamura A, Sunderajan P, Brown ES. Neurosteroid Levels in Patients With Bipolar Disorder and a History of Cannabis Use Disorders. Journal of Clinical Psychopharmacology. 2017. PMID 29045302. (accessed 2026-05-11)
[peltier2024ptsd_aud] Peltier MR, Verplaetse TL, Altemus M, Zakiniaeiz Y, Ralevski EA, Mineur YS, Gueorguieva R, Picciotto MR, Cosgrove KP, Petrakis I, McKee SA. The role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications. Frontiers in Neuroendocrinology. 2024. PMID 38184208. (accessed 2026-05-11)
[tomaselli2019pathway] Tomaselli G, Vallee M. Stress and drug abuse-related disorders: The promising therapeutic value of neurosteroids focus on pregnenolone-progesterone-allopregnanolone pathway. Frontiers in Neuroendocrinology. 2019. PMID 31525393. (accessed 2026-05-11)
[boero2020allopreg] Boero G, Porcu P, Morrow AL. Pleiotropic actions of allopregnanolone underlie therapeutic benefits in stress-related disease. Neurobiology of Stress. 2020. PMID 31879693. (accessed 2026-05-11)
[locci2017stress] Locci A, Pinna G. Neurosteroid biosynthesis down-regulation and changes in GABA(A) receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment. British Journal of Pharmacology. 2017. PMID 28456011. (accessed 2026-05-11)
[holsboer1994steroid] Holsboer F, Grasser A, Friess E, Wiedemann K. Steroid effects on central neurons and implications for psychiatric and neurological disorders. Annals of the New York Academy of Sciences. 1994. PMID 7825889. (accessed 2026-05-11)
[marecki2023zuranolone] Marecki R, Kaluska J, Kolanek A, Hakalo D, Waszkiewicz N. Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review. Frontiers in Psychiatry. 2023. PMID 38116383. (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
How to access
How to Access Pregnenolone
Compounded Pregnenolone is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Pregnenolone, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Pregnenolone.
